17,261 trials
Acute Bilineal Leukemia · Acute Biphenotypic Leukemia · Acute Leukemia of Ambiguous Lineage
Primary: Participants Complete Response — 9 Participants
Leukemia, Myeloid, Acute
Primary: Phase I: Number of Patients With Dose Limiting Toxicity (DLT(s)) During First Treatment Cycle — 0; 0; 0; 1 Participants
Prostate Cancer
Primary: Progression-free Survival (PFS) at 36 Months (3 Years) — 69.2 percentage of participants
Cancer Cachexia
Primary: Change of Body Weight — 0; 0.2 kg
Malaria
Primary: Number of Participants With Adverse Events Within 7 Days After Each Vaccine Administration — 51; 43; 43 Participants
Prostate Cancer
Primary: Pathology Status — 2.37; 1.73 number of positive cores
Alzheimer Disease
Primary: Annualized Rate of Change in Tau Burden — 0.0124; 0.0254 SUVR per year — p=0.1953
Nasopharyngeal Carcinoma
Primary: Objective Response Rate (ORR) Assess by Independent Review Committee (IRC) — 28.3 percentage of participants
Hepatocellular Carcinoma Non-Resectable
Primary: Objective Response Rate — 11.9; 16.7 percentage of participants
Acute Lymphoblastic Leukemia
Primary: Pharmacokinetics ASNase Activity >100 U/L at 14 Days — 92.5 percentage of patients
Hidradenitis Suppurativa · Acne Inversa
Primary: Percentage of Subjects Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12. — 30.8; 22.4; 35.1 percentage of participants — p=0.1321
Solid Tumors Harboring a BRAF V600 Mutation
Primary: Number of Participants With Dose Limiting Toxicities (DLTs): Phase 1b — 0; 0; 0; 0 Participants
Locally Advanced Esophageal and Gastric Cancers (EGC)
Primary: Number of Participants With Pathologic Complete Response (pCR) — 11 Participants
Wolfram Syndrome · Diabetes Mellitus · Optic Nerve Atrophy
Primary: Number of Participants With Treatment-related Adverse Events as Assessed by Liver Function Tests — 0; 0; 0; 2 Participants
Gastric Cancer · Esophagus Cancer
Primary: Months of Progression-free Survival (PFS) — 7.6 months — p=0.02